Amgen Inc
USUSDAmgen Inc (US:AMGN) — Biotechnology: Biological Products (No Diagnostic Substances). Število borz, na katerih se trgujejo delnice družbe: 4. Na tej strani — cena in graf, dividende, največji imetniki in zgodovina števila delnic.
O podjetju
- Spletna stran
- amgen.com
- Odnosi z vlagatelji
- investors.amgen.com/
- Sektor
- Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
- Sedež
- Thousand Oaks, United States
- Izvršni direktor
- Mr. Robert A. Bradway
- Zaposleni
- 17 900
- Ustanovljena
- 1980
- Delnice v obtoku
- 540.63 mio. na dan 2026-07-30
- Prosto prenosljive delnice
- 539.16 mio.
- Tržna kapitalizacija
- 226.05 mrd. USD
- Notranje osebe
- 0.23%
- Institucionalni vlagatelji
- 85.02%
- Panoga (SIC)
- Biological Products, (No Diagnostic Substances)
- Pravna oblika
- XTIQ
- ISIN
- US0311621009
- LEI
- 62QBXGPJ34PQ72Z12S66
- Delež izplačila
- 60.4%
- FCF
- 10.2 mrd. USD52%
- Dolg
- 57.3 mrd. USD4.3 let FCF
- Dividendni staž
- 15 let
- Dobički, FCF in izplačane dividende — za 12 mesecev do 30.06.2026 (najnovejše poročilo podjetja).
Opis
Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel for the treatment of rheumatoid arthritis, plaque psoriasis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including PROLIA, REPATHA, OTEZLA, ENBREL, EVENITY, XGEVA, TEPEZZA, BLINCYTO, NPLATE, TEZSPIRE, KYPROLIS, ARANESP, KRYSTEXXA AND VECTIBIX, MVASI, PAVBLU, UPLIZNA, IMDELLTRA/IMDYLLTRA, AMJEVITA/AMGEVITA, TAVNEOS, NEULASTA, LUMAKRAS/LUMYKRAS, RAVICTI, PARSABIV, AIMOVIG, WEZLANA/WEZENLA, AND PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; BEONE MEDICINES LTD. to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. The company was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Dividende
Amgen Inc (AMGN) izplačuje dividende četrtletno. V zadnjih 12 mesecih je bilo plačanih 9.94 USD na delnico (plačila: 4). To je približno 2.44% trenutne cene delnice. Glede na zgodovino izplačil se naslednji datum ex-dividende pričakuje okoli 20.11.2026. Leta neprekinjenih dividend: 15.
| Ex-datum | Izplačilo | Znesek | % | Vrsta | Oznaka |
|---|---|---|---|---|---|
| 2026-08-21 | 2026-09-11 | 2.5200 USD | 0.6/2.4 % | četrtletno | US:AMGN |
| 2026-05-15 | 2026-06-05 | 2.5200 USD | 0.6/2.4 % | četrtletno | US:AMGN |
| 2026-02-13 | 2026-03-06 | 2.5200 USD | 0.6/2.4 % | četrtletno | US:AMGN |
| 2025-11-21 | 2025-12-12 | 2.3800 USD | 0.6/≈2.3 % | četrtletno | US:AMGN |
| 2025-08-22 | 2025-09-12 | 2.3800 USD | 0.6/≈2.3 % | četrtletno | US:AMGN |
| 2025-05-16 | 2025-06-06 | 2.3800 USD | 0.6/≈2.3 % | četrtletno | US:AMGN |
Novice ta teden
Novic s spletnega mesta podjetja še ni.
Največji imetniki
| Imetnik | Delež | Delnice | Datum poročila |
|---|---|---|---|
| Blackrock Inc. | 9.13% | 49.36 mio. | 2026-06-30 |
| Vanguard Capital Managem… | 6.52% | 35.25 mio. | 2026-06-30 |
| State Street Corporation | 5.65% | 30.56 mio. | 2026-06-30 |
| Capital World Investors | 5.38% | 29.08 mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 17.13 mio. | 2026-06-30 |
| Invesco Ltd. | 3.02% | 16.32 mio. | 2026-06-30 |
| Geode Capital Management… | 2.9% | 15.7 mio. | 2026-06-30 |
| Charles Schwab Investmen… | 2.78% | 15.03 mio. | 2026-06-30 |
| Vanguard Portfolio Manag… | 2.75% | 14.85 mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.59% | 13.99 mio. | 2026-06-30 |
| Morgan Stanley | 2.53% | 13.65 mio. | 2026-06-30 |
| Invesco QQQ Trust, Serie… | 2.15% | 11.61 mio. | 2026-08-31 |
| SCHWAB STRATEGIC TRUST-S… | 1.81% | 9.79 mio. | 2026-05-31 |
| Income Fund of America | 1.44% | 7.76 mio. | 2026-06-30 |
| iShares Trust-iShares Co… | 1.35% | 7.28 mio. | 2026-07-31 |
| Wells Fargo & Company | 1.34% | 7.24 mio. | 2026-06-30 |
| AMERICAN BALANCED FUND | 1.31% | 7.09 mio. | 2026-06-30 |
| Fidelity Concord Street… | 1.29% | 6.98 mio. | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.22% | 6.6 mio. | 2026-08-31 |
| WASHINGTON MUTUAL INVEST… | 1.16% | 6.27 mio. | 2026-06-30 |
| BRADWAY ROBERT A (Chief… | ≈0.12% | 657 299 | 2026-05-05 |
| SANTOS ESTEBAN (Officer) | ≈0.02% | 84 279 | 2026-05-05 |
| GORDON MURDO (Officer) | ≈0.01% | 51 837 | 2026-05-05 |
| GRIFFITH PETER H. (Chief… | ≈0.01% | 50 706 | 2026-05-05 |
| REESE DAVID M. (Chief Te… | ≈0.01% | 42 812 | 2026-05-05 |
| GRAHAM JONATHAN P (Gener… | ≈0.01% | 40 211 | 2026-05-05 |
| BRADNER JAMES E. (Office… | ≈0.01% | 30 462 | 2026-05-05 |
| ECKERT ROBERT ANDREW (Di… | ≈0% | 26 251 | 2026-05-19 |
| JACKS TYLER (Director) | ≈0% | 18 284 | 2026-05-19 |
| KULLMAN ELLEN JAMISON (D… | ≈0% | 14 536 | 2026-05-19 |
